| 摘要 |
FIELD: chemistry.SUBSTANCE: invention relates to heterocyclic compound of formulaor to its pharmaceutically acceptable salt, where Alk represents linear Calkylene group, branched Calkylene group or Calkylene group, which has ring structure, where part of carbon atoms, constituting ring structure can be optionally substituted with oxygen atom, in ring X, Xrepresents N or CR, Xrepresents N or CR, Xrepresents CR, Xrepresents N or CR, where R, R, Rand Reach independently represents hydrogen atom; linear or branched Calkyl group; linear or branched Calcoxygroup; or halogen atom, in ring Y, Yrepresents CR, Yrepresents N or CR, Yrepresents N or CR, Yrepresents N or CR, R, R, Rand Reach independently represents hydrogen atom; linear or branched Calkyl group, which can be substituted with halogen atom(s); Calkyl group, which has ring structure; linear or branched Calkoxygroup; halogen atom or cyanogroup, in ring Z, Rrepresents linear or branched Calkyl group, which can be substituted with halogen atom(s), or Calkyl group, which has ring structure, which can be substituted with halogen atom(s). Invention also relates to particular compounds, DGAT1 inhibitor based on formula (I) compound, application of formula (I) compound, method of prevention or treatment of diseases, mediated by DGAT1 inhibition.EFFECT: obtained are novel compounds, possessing useful biological activity.19 cl, 19 tbl, 149 ex |
